Male Hypogonadism – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Male Hypogonadism – Drugs In Development, 2024 report and make more profitable business decisions.
Male hypogonadism is a condition in which the body doesn’t produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass, and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles, and untreated sleep apnea. Treatment includes hormone replacement.
The Male Hypogonadism drugs in development market research report provide comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Male Hypogonadism | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 22 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Male Hypogonadism therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Male Hypogonadism pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Male Hypogonadism treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAcesis Holdings Corp
Beijing FuKangren Bio-pharm Tech Co Ltd
Chong Kun Dang Pharmaceutical Corp.
Diurnal Group Plc
Endoceutics Inc
Function Promoting Therapies LLC
IASO BioMed Inc
Lennham Pharmaceuticals Inc
Lipocine Inc
M et P Pharma AG
Massachusetts General Hospital
Medlab Clinical Ltd
Mereo Biopharma Group Plc
MHB Labs
Shanghai Jing Ze Biotechnology Co Ltd
Solural Pharma ApS
TesoRx Pharma LLC
Transdermal Delivery Solutions Corp
Viramal Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Male Hypogonadism reports